Novartis

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals,...

Influenza Vaccine Novartis

Rabies Vaccine Novartis

Influenza Vaccine H5N1 Novartis

Interleukin-2 receptor Mab rDNA Novartis

FDA panel backs Novartis cystic fibrosis drug

WASHINGTON (Reuters) - Drug advisers on Wednesday backed a new form of Novartis AG's inhaled antibiotic that treats a lung infection linked to cystic fibrosis.

U.S. FDA panel backs Novartis cystic fibrosis drug

WASHINGTON, Sept 5 (Reuters) - U.S. drug advisers on Wednesday backed a novel form of Novartis AG's inhaled antibiotic that treats a lung infection linked to cystic fibrosis.

UPDATE 1-U.S. FDA panel backs Novartis cystic fibrosis drug

WASHINGTON, Sept 5 (Reuters) - U.S. drug advisers on Wednesday backed a new form of Novartis AG's inhaled antibiotic that treats a lung infection linked to cystic fibrosis.

Novartis: M&A activity 2005-2013

Novartis has announced 18 M&A deals since 2005, with the lead deals being the acquisition of Alcon and Fougera. Abstracted from: Partnering Deals and Alliances with Novartis Novartis is involved i...

Lincoln Chiropractor Wins "Best of Yuba" Award for Third Year

LINCOLN, Calif., June 10, 2012 (GLOBE NEWSWIRE) -- Advanced Spinal Rehab, Inc. announced that Dr. Larry W. Gies DC has been selected for the 2012 Best of Yuba City Award in the Chiropractic Clinics c...

Lincoln Property Company Boosts Occupancy Rates With ReachLocal

WOODLAND HILLS, Calif., Feb. 13, 2013 (GLOBE NEWSWIRE) -- ReachLocal, Inc. (Nasdaq:RLOC), a leader in local online marketing solutions for small- and medium-sized businesses (SMBs), today announced t...

Novartis says Afinitor reduces tumors in rare genetic disease

ZURICH, Jan 11 (Reuters) - Novartis said its drug Afinitor helped reduce kidney tumors linked to tuberous sclerosis complex, or TSC, a rare genetic disease that causes tumors to grow in the brain and...

Lincoln Educational Services Corporation Reports Second Quarter 2012 Results

WEST ORANGE, N.J., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation (Nasdaq:LINC) ("Lincoln") today reported second quarter results. Highlights: Revenue of $100.4 mill...

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease.

Allosteric modulators of the calcium-sensing receptor: turning news into distinct views.

Editorial: Peer across the barrier--new live transmissions from the intestinal mucosa.

Comments on 'Adaptive increase in sample size when interim results are promising: A practical guide with examples' by C. R. Mehta and S. J. Pocock.

List of Drugs in Development for Neurodegenerative Diseases: Update June 2010.

No abstract available.